SELLAS Life Sciences (SLS) Current Leases (2010 - 2026)
SELLAS Life Sciences (SLS) reported Current Leases of $562000.0 for Q1 2026, little changed year-over-year from $561000.0 in Q1 2025, and up 3.31% on a QoQ basis from $544000.0 in Q4 2025.
SELLAS Life Sciences (SLS) has 13 years of Current Leases data on file, last reported at $562000.0 in Q1 2026.
- Quarterly Current Leases changed 0.18% year-over-year to $562000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $562000.0 (changed 0.18% YoY) and the FY2025 annual result came in at $544000.0, changed 0.0% from the prior year.
- Current Leases grew to $562000.0 in Q1 2026 per SLS's latest filing, from $544000.0 in the prior quarter.
- Across five years, Current Leases topped out at $599000.0 in Q3 2025 and bottomed at $325000.0 in Q1 2022.
- The 5-year median for Current Leases is $488000.0 (2024), against an average of $480294.1.
- The widest annual swing landed in 2022, when Current Leases jumped 87.88%; it then changed 0.0% in 2025.
- Tracing SLS's Current Leases over 5 years: stood at $372000.0 in 2022, then rose by 19.89% to $446000.0 in 2023, then grew by 21.97% to $544000.0 in 2024, then changed by 0.0% to $544000.0 in 2025, then advanced by 3.31% to $562000.0 in 2026.
- Per Business Quant, the three latest SLS Current Leases figures stand at $562000.0 (Q1 2026), $544000.0 (Q4 2025), and $599000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 83,991.00 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 7.40 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 720.00 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 45.66 Mn |
| 10 | SELLAS Life Sciences | 1.61 Bn | 1.61 Bn | - | 562,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 562,000.00 |
| Dec 31, 2025 | 544,000.00 |
| Sep 30, 2025 | 599,000.00 |
| Jun 30, 2025 | 580,000.00 |
| Mar 31, 2025 | 561,000.00 |
| Dec 31, 2024 | 544,000.00 |
| Sep 30, 2024 | 576,000.00 |
| Jun 30, 2024 | 531,000.00 |
| Mar 31, 2024 | 488,000.00 |
| Dec 31, 2023 | 446,000.00 |
| Sep 30, 2023 | 466,000.00 |
| Jun 30, 2023 | 447,000.00 |
| Mar 31, 2023 | 427,000.00 |
| Dec 31, 2022 | 372,000.00 |
| Sep 30, 2022 | 356,000.00 |
| Jun 30, 2022 | 341,000.00 |
| Mar 31, 2022 | 325,000.00 |
| Dec 31, 2021 | 198,000.00 |
| Sep 30, 2021 | 190,000.00 |
| Jun 30, 2021 | 182,000.00 |
| Mar 31, 2021 | 174,000.00 |
| Dec 31, 2020 | 166,000.00 |
| Sep 30, 2020 | 136,000.00 |
| Jun 30, 2020 | 100,000.00 |
| Mar 31, 2020 | 123,000.00 |
| Dec 31, 2019 | 217,000.00 |
| Sep 30, 2019 | 306,000.00 |
| Jun 30, 2019 | 362,000.00 |
| Mar 31, 2019 | 359,000.00 |
| Sep 30, 2014 | 6,000.00 |
| Jun 30, 2014 | 6,000.00 |
| Mar 31, 2014 | 6,000.00 |
| Dec 31, 2013 | 6,000.00 |
| Sep 30, 2013 | 6,000.00 |
| Jun 30, 2013 | 6,000.00 |
| Mar 31, 2013 | 6,000.00 |
| Dec 31, 2012 | 6,000.00 |
| Sep 30, 2012 | 6,000.00 |
| Mar 31, 2012 | 24,000.00 |
| Dec 31, 2011 | 35,000.00 |
| Sep 30, 2011 | 65,000.00 |
| Jun 30, 2011 | 59,000.00 |
| Dec 31, 2010 | 51,000.00 |